Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Clinical Studies of Escherichia coli O157:H7 Conjugate Vaccines in Adults and Young Children.

Szu SC, Ahmed A.

Microbiol Spectr. 2014 Dec;2(6). doi: 10.1128/microbiolspec.EHEC-0016-2013.

PMID:
26104443
2.

Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.

Szu SC, Lin KF, Hunt S, Chu C, Thinh ND.

Vaccine. 2014 May 7;32(22):2618-22. doi: 10.1016/j.vaccine.2014.03.023. Epub 2014 Mar 21.

3.
4.

Development of Vi conjugate - a new generation of typhoid vaccine.

Szu SC.

Expert Rev Vaccines. 2013 Nov;12(11):1273-86. doi: 10.1586/14760584.2013.845529. Review.

PMID:
24156285
5.
6.

A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.

Szu SC, Hunt S, Xie G, Robbins JB, Schneerson R, Gupta RK, Zhao Z, Tan X.

Vaccine. 2013 Apr 8;31(15):1970-4. doi: 10.1016/j.vaccine.2013.02.006. Epub 2013 Feb 17.

7.

Early-life and contemporaneous nutritional and environmental predictors of antibody response to vaccination in young Gambian adults.

Moore SE, Richards AA, Goldblatt D, Ashton L, Szu SC, Prentice AM.

Vaccine. 2012 Jul 6;30(32):4842-8. doi: 10.1016/j.vaccine.2012.05.009. Epub 2012 May 18.

8.

Specific Acquired Immunity.

Robbins JB, Schneerson R, Szu SC.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 8.

9.

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.

Thiem VD, Lin FY, Canh DG, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Schneerson R, Szu SC.

Clin Vaccine Immunol. 2011 May;18(5):730-5. doi: 10.1128/CVI.00532-10. Epub 2011 Mar 16.

10.

An outbreak of Salmonella Paratyphi A in a boarding school: a community-acquired enteric fever and carriage investigation.

Yang HH, Gong J, Zhang J, Wang ML, Yang J, Wu GZ, Quan WL, Gong HM, Szu SC.

Epidemiol Infect. 2010 Dec;138(12):1765-74. doi: 10.1017/S0950268810001986. Epub 2010 Aug 27.

11.

Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, Clemens JD.

Clin Vaccine Immunol. 2010 Jan;17(1):73-9. doi: 10.1128/CVI.00266-09. Epub 2009 Nov 4.

12.

Revaccination does not improve an observed deficit in antibody responses in Pakistani adults born of a lower birth weight.

Moore SE, Jalil F, Szu SC, Hahn-Zoric M, Prentice AM, Hanson LA.

Vaccine. 2008 Jan 10;26(2):158-65. Epub 2007 Nov 26.

PMID:
18068877
13.

Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children.

Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC.

J Infect Dis. 2006 Feb 15;193(4):515-21. Epub 2006 Jan 13.

PMID:
16425130
14.

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC.

Infect Immun. 2004 Nov;72(11):6586-8.

15.

Birth weight predicts response to vaccination in adults born in an urban slum in Lahore, Pakistan.

Moore SE, Jalil F, Ashraf R, Szu SC, Prentice AM, Hanson LA.

Am J Clin Nutr. 2004 Aug;80(2):453-9.

PMID:
15277170
16.
17.

Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.

Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, Szu SC.

N Engl J Med. 2003 Oct 2;349(14):1390-1. No abstract available.

PMID:
14523155
18.

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.

Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.

N Engl J Med. 2001 Apr 26;344(17):1263-9.

20.
21.

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB, Li J, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 2000 Mar;68(3):1529-34.

22.

Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.

Konadu E, Donohue-Rolfe A, Calderwood SB, Pozsgay V, Shiloach J, Robbins JB, Szu SC.

Infect Immun. 1999 Nov;67(11):6191-3.

23.

Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.

Infect Immun. 1999 Nov;67(11):5806-10.

24.
25.

Measurement of human serum IgG antibodies or a surrogate is sufficient to standardize (predict efficacy) vaccines.

Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY.

Dev Biol Stand. 1998;95:221-2. No abstract available.

PMID:
9855435
26.

Standardization may suffice for licensure of conjugate vaccines.

Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY, Gotschlich EC.

Dev Biol Stand. 1998;95:161-7. Review.

PMID:
9855427
27.
28.

Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.

Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 1998 Jul;66(7):3095-9.

29.

On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba.

Wang J, Villeneuve S, Zhang J, Lei P, Miller CE, Lafaye P, Nato F, Szu SC, Karpas A, Bystricky S, Robbins JB, Kovác P, Fournier JM, Glaudemans CP.

J Biol Chem. 1998 Jan 30;273(5):2777-83.

30.
31.

Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Kossaczka Z, Bystricky S, Bryla DA, Shiloach J, Robbins JB, Szu SC.

Infect Immun. 1997 Jun;65(6):2088-93.

33.

Characterization of colominic acid by circular dichroism and viscosity analysis.

Bystricky S, Pavliak V, Szu SC.

Biophys Chem. 1997 Jan 31;63(2-3):147-52.

PMID:
9108689
35.

Hypothesis: how licensed vaccines confer protective immunity.

Robbins JB, Schneerson R, Szu SC.

Adv Exp Med Biol. 1996;397:169-82. Review.

PMID:
8718596
36.

Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi.

Liao J, Nickerson KG, Bystricky S, Robbins JB, Schneerson R, Szu SC, Kabat EA.

Infect Immun. 1995 Nov;63(11):4429-32.

38.
39.

Circular dichroism of the O-specific polysaccharide of Vibrio cholerae O1 and some related derivatives.

Bystrický S, Szu SC, Gotoh M, Kovác P.

Carbohydr Res. 1995 Apr 30;270(2):115-22.

PMID:
7585695
40.
41.
42.

Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, Bryla DA, Robbins JB.

Infect Immun. 1994 Oct;62(10):4440-4.

43.
44.
46.

Relation between structure and immunologic properties of the Vi capsular polysaccharide.

Szu SC, Li XR, Stone AL, Robbins JB.

Infect Immun. 1991 Dec;59(12):4555-61.

47.

Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL.

Schneerson R, Fattom A, Szu SC, Bryla D, Ulrich JT, Rudbach JA, Schiffman G, Robbins JB.

J Immunol. 1991 Oct 1;147(7):2136-40.

PMID:
1918948
48.

O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases.

Robbins JB, Chu C, Watson DC, Szu SC, Daniels EM, Lowe CU, Schneerson R.

Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S362-5. Review.

PMID:
2047664
49.

Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.

Fattom A, Lue C, Szu SC, Mestecky J, Schiffman G, Bryla D, Vann WF, Watson D, Kimzey LM, Robbins JB, et al.

Infect Immun. 1990 Jul;58(7):2309-12.

50.

Supplemental Content

Support Center